Patents by Inventor Narendra R. Vyavahare
Narendra R. Vyavahare has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220089706Abstract: Antibodies and antigen binding fragments thereof that specifically recognize and bind an epitope of elastin that is exposed and accessible in degraded elastic fiber are described. The antibodies and/or antigen binding fragments can be operably linked to a secondary component, including biologically active agents such as therapeutics and/or imaging agents. Optionally, the antibodies and/or antigen binding fragments thereof can be attached to a surface of a carrier, such as a particle, for specific binding and delivery of the carried agents to degraded elastic fiber.Type: ApplicationFiled: January 22, 2019Publication date: March 24, 2022Inventors: NARENDRA R. VYAVAHARE, CHARLES D. RICE, NASIM NOSOUDI, SAKETH KARAMCHED, VAIDEESH PARASARAM
-
Publication number: 20220073869Abstract: Embodiments of the present specification provide systems and methods for holding one or more tissues, such as veins, such that the tissue remains open in a chamber while undergoing orbital shaking with various solutions and to allow uniform treatment during a decellularization process. A frame is held on a stand to which the tissues are attached and comprises a tension inducing mechanism to cause the tissues to controllably stretch. The frame is removed from the stand, with the tissue attached to it, and placed in a decellularization chamber for uniform treatment of the tissue.Type: ApplicationFiled: September 3, 2021Publication date: March 10, 2022Inventors: Narendra R. Vyavahare, Teodor Dan Simionescu, Agnes Nagy-Mehesz, Ajay Houde
-
Patent number: 8435553Abstract: A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.Type: GrantFiled: December 21, 2011Date of Patent: May 7, 2013Assignee: Clemson University Research Foundation (CURF)Inventors: Narendra R. Vyavahare, Jason C. Isenburg, Dan T. Simionescu
-
Publication number: 20120114732Abstract: A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.Type: ApplicationFiled: December 21, 2011Publication date: May 10, 2012Inventors: Narendra R. Vyavahare, Jason C. Isenburg, Dan T. Simionescu
-
Patent number: 8142805Abstract: Disclosed are implantable tissues including one or more enzyme inhibitors bound in the tissues, bioprostheses including the tissue, and methods for incorporating enzyme inhibitors in implantable tissues. Disclosed tissue can exhibit increased resistance to degradation, and specifically, degradation due to enzyme activity following implantation. Moreover, the disclosed methods can lead to increased levels of beneficial components bound in implantable tissues following a fixation/stabilization protocol. Increased levels of beneficial agents in an implantable tissue can further improve the implantable tissues and bioprostheses incorporating the tissues through improved mechanical characteristics and longer lifespan.Type: GrantFiled: November 5, 2007Date of Patent: March 27, 2012Assignee: Clemson University Research FoundationInventors: Narendra R. Vyavahare, Devanathan Raghavan
-
Patent number: 8100961Abstract: A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.Type: GrantFiled: March 29, 2010Date of Patent: January 24, 2012Assignee: Clemson University Research Foundation (CURF)Inventors: Narendra R. Vyavahare, Jason C. Isenburg, Dan T. Simionescu
-
Publication number: 20100185272Abstract: A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.Type: ApplicationFiled: March 29, 2010Publication date: July 22, 2010Inventors: Narendra R. Vyavahare, Jason C. Isenburg, Dan T. Simionescu
-
Patent number: 7713543Abstract: A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.Type: GrantFiled: July 10, 2007Date of Patent: May 11, 2010Assignee: Clemson University Research FoundationInventors: Narendra R. Vyavahare, Jason C. Isenburg, Dan T. Simionescu
-
Publication number: 20090214654Abstract: Delivery vehicles for controlled release of connective tissue stabilization agent for the treatment of vascular aneurysms are described. The delivery vehicle generally is combined with a connective tissue stabilization agent to form a therapeutic composition. The treatment of an aneurysm can be achieved through release of connective tissue stabilization agent from the delivery vehicle to the aneurysm. The connective tissue stabilization agent can be collagen stabilization agent, elastin stabilization agent, or a combination thereof. The aneurysm can be treated individually, simultaneously or sequentially with collagen stabilization agent and elastin stabilization agent embedded in separate delivery vehicles.Type: ApplicationFiled: February 20, 2009Publication date: August 27, 2009Inventors: Jason C. Isenburg, Narendra R. Vyavahare, Matthew F. Ogle
-
Patent number: 7252834Abstract: A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.Type: GrantFiled: March 23, 2006Date of Patent: August 7, 2007Assignee: Clemson University Research Foundation (CURF)Inventors: Narendra R. Vyavahare, Jason C. Isenburg, Dan T. Simionescu
-
Publication number: 20040158320Abstract: A biomaterial useful for bioprostheses such as bioprosthetic heart valves is provided in which the fixed tissue has improved elastic properties. The high elastin-containing biomaterial is further characterized by having anisotropic properties wherein the biological material has a greater stiffness in one direction and a greater elasticity in a cross direction. For instance, the biological material has an elastin content of about 30% by weight. In one embodiment, the biological material is vena cava tissue.Type: ApplicationFiled: November 24, 2003Publication date: August 12, 2004Inventors: Dan T. Simionescu, Narendra R. Vyavahare